Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
DJ Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
1157 GMT - Roche's sales of Covid-19 tests will continue for longer than originally envisaged and will remain high into 3Q, as it is taking longer for the vaccination rollout to be completed, Credit Suisse says. The Swiss pharma major's share in PCR testing is strong and likely to be sustained for longer, it says. Furthermore, PCR tests will continue to be necessary even among vaccinated patients, who are likely to have much lower infection levels and so necessitate a more accurate test, the bank says, adding that Covid-19 is seen remaining a market opportunity for Roche in the low-single digit billion Swiss francs. Roche trades 0.8% lower at CHF306.80. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
March 24, 2021 07:57 ET (11:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk
DJ羅氏從新冠肺炎獲得的好處將在疫苗推出緩慢的情況下繼續-市場對話
1157 GMT - Roche's sales of Covid-19 tests will continue for longer than originally envisaged and will remain high into 3Q, as it is taking longer for the vaccination rollout to be completed, Credit Suisse says. The Swiss pharma major's share in PCR testing is strong and likely to be sustained for longer, it says. Furthermore, PCR tests will continue to be necessary even among vaccinated patients, who are likely to have much lower infection levels and so necessitate a more accurate test, the bank says, adding that Covid-19 is seen remaining a market opportunity for Roche in the low-single digit billion Swiss francs. Roche trades 0.8% lower at CHF306.80. (cecilia.butini@wsj.com)
1157GMT-瑞士信貸稱,羅氏新冠肺炎檢測的銷售將持續比最初預想的更長時間,並將保持高位進入第三季度,因疫苗推廣完成所需的時間更長。該公司表示,這家瑞士製藥巨頭在PCR檢測中的份額很大,可能會持續更長時間。此外,世行表示,即使是在接種疫苗的患者中,聚合酶鏈反應檢測也將繼續是必要的,這些患者的感染水平可能要低得多,因此需要進行更準確的檢測。該行補充説,新冠肺炎被視為羅氏在低個位數10億瑞士法郎的市場機會。羅氏股價下跌0.8%,至306.80瑞士法郎。(cecilia.butini@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
March 24, 2021 07:57 ET (11:57 GMT)
2021年3月24日東部時間07:57(格林尼治標準時間11:57)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧